scholarly journals Spanish rare disease registries research network: first results of Spain-RDR’s project in Navarre

2019 ◽  
Vol 42 (2) ◽  
2015 ◽  
Vol 18 (2) ◽  
pp. 113-122 ◽  
Author(s):  
Michele Santoro ◽  
Alessio Coi ◽  
Michele Lipucci Di Paola ◽  
Anna Maria Bianucci ◽  
Sabina Gainotti ◽  
...  

Author(s):  
Ana Maria Martins ◽  
Marcelo Kerstenezky ◽  
Adriana Linares ◽  
Juan Politei ◽  
Regina Kohan ◽  
...  

2013 ◽  
Vol 16 (6) ◽  
pp. 288-298 ◽  
Author(s):  
D. Taruscio ◽  
S. Gainotti ◽  
E. Mollo ◽  
L. Vittozzi ◽  
F. Bianchi ◽  
...  

2016 ◽  
Vol 19 (2) ◽  
pp. 108-115 ◽  
Author(s):  
Alessio Coi ◽  
Michele Santoro ◽  
Ana Villaverde-Hueso ◽  
Michele Lipucci Di Paola ◽  
Sabina Gainotti ◽  
...  

2017 ◽  
Vol 120 (1-2) ◽  
pp. S43
Author(s):  
Danielle Dong ◽  
Julie Batista ◽  
Katherine Belk ◽  
Marta Cizmarik ◽  
Cinde Clatterbuck ◽  
...  

2006 ◽  
Vol 8 (1) ◽  
pp. 115-121

The German Research Network On Schizophrenia (GRNS) is a nationwide network currently comprising 16 psychiatric university departments and 14 state and district hospitals, as well as six local networks of psychiatric practices and general practitioners collaborating on about 25 interrelated, multicenter projects on schizophrenia research. The GRNS aims to intensify collaboration and knowledge exchange between leading research institutions and qualified routine care facilities, both within (horizontal network) and between (vertical network) the two levels of research and care, in order to create the scientific preconditions for optimization of the management of schizophrenia. The concept and the first results of studies aiming at the investigation of (i) strategies for early detection and early intervention in the prodromal stage of psychosis; (ii) treatment in first-episode schizophrenia; (iii) quality management; and (iv) destigmatization, are described as examples of this effort.


2021 ◽  
Author(s):  
Rajaram Kaliyaperumal ◽  
Mark D Wilkinson ◽  
Pablo Alarcon Moreno ◽  
Nirupama Benis ◽  
Ronald Cornet ◽  
...  

Background: The European Platform on Rare Disease Registration (EU RD Platform) aims to address the fragmentation of European rare disease (RD) patient data, scattered among hundreds of independent and non-coordinating registries, by establishing standards for integration and interoperability. The first practical output of this effort was a set of 16 Common Data Elements (CDEs) that should be implemented by all RD registries. Interoperability, however, requires decisions beyond data elements - including data models, formats, and semantics. Within the European Joint Programme on Rare Disease (EJP RD), we aim to further the goals of the EU RD Platform by generating reusable RD semantic model templates that follow the FAIR Data Principles. Results: Through a team-based iterative approach, we created semantically grounded models to represent each of the CDEs, using the SemanticScience Integrated Ontology as the core framework for representing the entities and their relationships. Within that framework, we mapped the concepts represented in the CDEs, and their possible values, into domain ontologies such as the Orphanet Rare Disease Ontology, Human Phenotype Ontology and National Cancer Institute Thesaurus. Finally, we created an exemplar, reusable ETL pipeline that we will be deploying over these non-coordinating data repositories to assist them in creating model-compliant FAIR data without requiring site-specific coding nor expertise in Linked Data or FAIR. Conclusions: Within the EJP RD project, we determined that creating reusable, expert-designed templates reduced or eliminated the requirement for our participating biomedical domain experts and rare disease data hosts to understand OWL semantics. This enabled them to publish highly expressive FAIR data using tools and approaches that were already familiar to them.


2011 ◽  
Vol 32 (10) ◽  
pp. 1073-1074
Author(s):  
Richard G. H. Cotton

2020 ◽  
Vol 21 (1) ◽  
Author(s):  
Johannes Boettcher ◽  
Bonnie Filter ◽  
Jonas Denecke ◽  
Amra Hot ◽  
Anne Daubmann ◽  
...  

Abstract Background Families of children with rare diseases (i.e., not more than 5 out of 10,000 people are affected) are often highly burdened with fears, insecurities and concerns regarding the affected child and its siblings. Although families caring for children with rare diseases are known to be at risk for mental disorders, the evaluation of special programs under high methodological standards has not been conducted so far. Moreover, the implementation of interventions for this group into regular care has not yet been accomplished in Germany. The efficacy and cost-effectiveness of a family-based intervention will be assessed. Methods/design The study is a 2x2 factorial randomized controlled multicenter trial conducted at 17 study centers throughout Germany. Participants are families with children and adolescents affected by a rare disease aged 0 to 21 years. Families in the face-to-face intervention CARE-FAM, online intervention WEP-CARE or the combination of both will be treated over a period of roughly 6 months. Topics discussed in the interventions include coping, family relations, and social support. Families in the control condition will receive treatment as usual. The primary efficacy outcome is parental mental health, measured by the Structured Clinical Interview for DSM-IV (SCID-I) by blinded external raters. Further outcomes will be assessed from the parents’ as well as the children’s perspective. Participants are investigated at baseline, 6, 12 and 18 months after randomization. In addition to the assessment of various psychosocial outcomes, a comprehensive health-economic evaluation will be performed. Discussion This paper describes the implementation and evaluation of two family-based intervention programs for Children Affected by Rare Disease and their Family’s Network (CARE-FAM-NET) in German standard care. A methodologically challenging study design is used to reflect the complexity of the actual medical care situation. This trial could be an important contribution to the improvement of care for this highly burdened group. Trial registration German Clinical Trials Register: DRKS00015859 (registered 18 December 2018) and ClinicalTrials.gov: NCT04339465 (registered 8 April 2020). Protocol Version: 15 August 2020 (Version 6.1). Trial status: Recruitment started on 1 January 2019 and will be completed on 31 March 2021.


Sign in / Sign up

Export Citation Format

Share Document